• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 5 - Establishing the Value of Immunotherapy in Oncology

Article

Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.

Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.

“Many of the new therapies, whether they be targeted agents or immunotherapies are extremely expensive,” he said. “We can get into long debate about what the right or fair price is, but I think because of the high cost, there is a lot of scrutiny in the managed care world to make sure that the right patient gets the treatment.”

He added that it can be difficult to know where treatments belong in the sequence of therapy. While some people are of the opinion that these treatments should be used earlier rather than later, payers prefer to manage to what the FDA decides.

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.